Skip to content

CLINICAL STUDY TO SEE THE EFFECT OF SOME AYURVEDIC FORMULATION IN THE TREATMENT OF SIMPLE ALLERGIC CONJUNCTIVITIS.

CLINICAL TRIAL TO EVALUATE THE EFFICACY OF SHALIPARNYADI SIDDHA GHRITA ASCHYOTANA IN MANAGEMENT OF VATAJA ABHISHYANDA.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045722
Enrollment
35
Registered
2022-09-21
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H108- Other conjunctivitis

Interventions

None listed

Sponsors

SANE GURUJI AROGYA KENDRA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients suffering from Vataja Abhishyanda with symptoms like Nistodana (pricking pain in eye), Stambana (loss or difficulty of ocular movements), Romaharsha (goose bumps/ horripilate), Sangharsha (foreign body sensation), Parushya (Dryness/ roughness), Shirobhitapa (Headache), Shishirashruta (Cold watery discharge) etc.

Exclusion criteria

Exclusion criteria: 1)Patients with Pittaja and Kaphaj Abhishyanda Lakshana. 2)Patients suffering with or having history of Coronavirus disease. 3)Patients with any other systemic diseases such as Allergic Rhinitis, Allergic Bronchitis, DM, HTN, etc. or any other severe ocular infections like Corneal Ulceration. 4)Patients with any autoimmune disorders for e.g. Rheumatoid Arthritis.

Design outcomes

Primary

MeasureTime frame
Symptoms like Netra Toda, Sangharsha, Shishirashruta and Alpa Shopha will be decreased, subject will get relief from Vataja Abhishyanda.Timepoint: 18 MONTHS

Secondary

MeasureTime frame
Further severe ocular complications are avoided.Timepoint: 18 MONTHS

Countries

India

Contacts

Public ContactPROF DR MRS NILAKSHI S PRADHAN

M.A.M.�S SUMATIBHAI SHAH AYURVED MAHAVIDYALAYA

drnspradhan@yahoo.com9423580963

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026